Recent Updates
Recently added Catalysts
TLX Negative Sentiment Score: 25/100

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Telix Pharmaceuticals Limited on behalf of its stockholders due to potential violations of federal securities laws. The investigation was announced following a subpoena received by Telix from the U.S. Securities and Exchange Commission, which seeks details regarding the company's prostate cancer drug disclosures. Following this news, Telix's stock price fell over 10%. Investors who incurred losses are encouraged to contact the law firm for further assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Telix is under investigation for potential violations of federal securities laws.
  • The company's stock has recently experienced a significant price drop following the subpoena disclosure.
  • Investors are encouraged to seek legal counsel due to the ongoing investigation.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) on behalf of Telix stockholders. Our investigation concerns whether Telix has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.
If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Telix Pharmaceuticals
Bragar Eagel & Squire

Frequently Asked Questions

How can I contact Bragar Eagel & Squire regarding Telix?

You can call Brandon Walker or Marion Passmore at (212) 355-4648.

What prompted the investigation into Telix Pharmaceuticals?

The U.S. SEC issued a subpoena regarding Telix's prostate cancer therapeutic disclosures.

What was the impact of the SEC subpoena on Telix's stock?

Telix's ADR price dropped $1.70, or 10.44%, to close at $14.58 following the news.

Is there a cost to discuss my legal rights with the firm?

No, there is no cost or obligation to discuss your legal rights.

What type of claims are being investigated against Telix?

The investigation concerns potential violations of federal securities laws by Telix.

Last updated: Sep 15, 2025